Ligand Pharmaceuticals (LGND) Tax Provisions (2010 - 2026)

Ligand Pharmaceuticals has disclosed Tax Provisions across 17 years of filings, most recently posting -$10.9 million for Q1 2026.

• Tax Provisions for Q1 2026 came in at -$10.9 million, down 41.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.3 million (up 209.95% YoY), and the FY2025 annual result was $34.5 million, up 426.82% from the prior year.
• Tax Provisions came in at -$10.9 million for Q1 2026 at Ligand Pharmaceuticals, down from $12.0 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $38.7 million in Q4 2022 to a low of -$13.5 million in Q2 2024.
• The 5-year median for Tax Provisions is $881000.0 (2023), against an average of $4.8 million.
• Across the five-year window, Tax Provisions plunged 1629.97% in 2024 and jumped 2764.83% in 2025, its largest moves.
• Ligand Pharmaceuticals' Tax Provisions stood at $38.7 million in 2022, then sank by 102.82% to -$1.1 million in 2023, then slumped by 643.54% to -$8.1 million in 2024, then jumped by 247.88% to $12.0 million in 2025, then sank by 190.98% to -$10.9 million in 2026.
• The last three Tax Provisions figures came in at -$10.9 million (Q1 2026), $12.0 million (Q4 2025), and $23.9 million (Q3 2025), per Business Quant data.